



VII CONGRESSO CATARINENSE  
DE OBSTETRÍCIA E GINECOLOGIA  
II Congresso Catarinense de Perinatologia

25 a 27 de junho de 2015 | Expoville | Joinville | SC

**Maria Elisabeth Lopes Moreira**

Declaração de conflito de interesse

Nestlé, Mead Jonhson e Danone nos anos  
2014-2015

# NUTRIÇÃO PARENTERAL

MARIA ELISABETH LOPES MOREIRA  
INSTITUTO FERNANDO FIGUEIRA/FIOCRUZ  
CLÍNICA PERINATAL LARANJEIRAS



VII CONGRESSO CATARINENSE DE  
OBSTETRÍCIA E GINECOLOGIA  
II CONGRESSO CATARINENSE DE  
PERINATOLOGIA

25 a 27 de junho de 2015 | Expoville | Joinville - SC



# Conflito de interesses

Declaro:

-Não recebo financiamentos para pesquisa ou salários de nenhuma empresa alimentícia

Nos últimos anos recebi financiamento da Mead Jonhson, Nestlé, Abbott e Pfizer para congressos

Realizo palestras em eventos patrocinados pela indústria

Recebo Financiamentos para pesquisa do CNPq e Faperj

COLLECTOR'S EDITION

# LIFE

## BORN TOO SOON

The high-tech,  
high-risk drama of  
keeping the tiniest  
babies alive



Jason Michael  
Waldmann Jr., who  
weighed only 1.2  
pounds at birth

MAY 2000/\$3.99  
0 70989 10099 2  
DISPLAY UNTIL MAY 30

## Vulnerabilidade dos pré-termos

- Orgãos e Sistemas Imaturos
- Ambiente desfavorável
- Limitações com volumes
- Gasto metabólico alto
- Doenças associadas a prematuridade
- Dificuldades operacionais de manter o aleitamento
- Repercussões a longo prazo da restrição de crescimento
- Metas “quase” inalcançáveis

# INDICAÇÕES

- Menores de 1500g
- Doenças gastrointestinais
- Situações onde a nutrição enteral não pode ser iniciada

# CONTEÚDO

- Proteína
- Lipídeos
- Água e Glicose
- Minerais
- Vitaminas
- Oligoelementos

# COMPOSIÇÃO DA NPT

**TABLE 1** Nutritional composition of a binary RTU premixed PS and a commercially premixed 3-CB for preterm infants compared with the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition recommendations for VLBW infants at the end of the first week of life<sup>1</sup>

Nutritional component/ (kg body weight · d)	Recent recommendations for VLBW infants at the end of the first week of life <sup>2</sup>	Binary RTU premixed PS <sup>3</sup>	Commercially premixed 3-CB <sup>4</sup>
Fluids, mL	—	165	128
Energy, kcal	90–120	118	117
Protein <sup>5</sup> , g	3.5–4.0	4.1	4.0
Glucose, g	13–18	18.8	17.1
Fat <sup>6</sup> , g	2–4	3.0 <sup>7</sup>	3.2
Sodium, mmol	2–7	2.4	2.8
Potassium, mmol	2–5	2.3	2.6
Chloride, mmol	2–7	3.0	4.0
Calcium, mmol	1.3–4.0	2.7	1.6
Phosphorus, mmol	1.0–2.5	2.7	1.6
Magnesium, mmol	0.2–0.4	0.25	0.55

<sup>1</sup> PS, parenteral solution; RTU, ready-to-use; VLBW, very-low-birth-weight; 3-CB, 3-chamber bag; —, not applicable.

<sup>2</sup> Source: references 4 and 5.

<sup>3</sup> Source: references 3 and 9.

<sup>4</sup> Numeta G13% E; Baxter Healthcare.

<sup>5</sup> Primene 10%; Baxter Healthcare.

<sup>6</sup> ClinOleic; Baxter Healthcare.

<sup>7</sup> Lipid provided separately.

# PROTEÍNA

- Iniciar logo após o nascimento
- Quantidade : 2,5 a 3,5 g/Kg/dia
- Soluções que contenham taurina
- 20 a 25 Kcal de calorias não proteicas são requeridas para cada grama de proteína para promover crescimento – evidência moderada

Uthaya S, Modi N. Practical preterm parenteral nutrition: Systematic literature review and recommendations for practice. 2014. Early Human Development.

Braake Te et al. Parenteral amino acid and energy administration to premature infants em early life. Semin Fetal Neonatal Med 2007

# LIPÍDEOS

- Alto valor calórico – soluções a 20 % 1g – 10 calorias
- Baixa Osmolaridade - veia periférica
- Lipoproteína lipase
- Soluções a 20% contem uma menor razão fosfolipide/troglicerideos  
– melhor clearance de triglycerideos
- **Tipos:**
  - Óleo de soja
  - Óleo de soja com triglycerideos de cadeia media
  - Óleo de soja + triglicerídeo de cadeia média + óleo de oliva + óleo de peixe

# LIPÍDEOS

**Table 1.** Comparison and Characteristics of Different Parenteral Lipid Emulsions

Product	Intralipid	SMOFlipid	ClinOleic	Omegaven	ClinOleic: Omegaven 1:1
<b>Oil source, %</b>					
Soybean	100	30	20	0	10
MCT	0	30	0	0	0
Olive oil	0	25	80	0	40
Fish oil	0	15	0	100	50
<b>Saturated FA, g/10 g ILE</b>					
Caprylic (8:0)		1.6			
Capric (10:0)		1.1			
Palmitic (16:0)	1.0	0.92	1.3	0.63	0.96
Stearic (18:0)	0.40	0.27	0.20	0.13	0.16
<b>Monounsaturated FA, g/10 g ILE</b>					
Oleic (18:1)	2.6	2.8	6.5	0.95	3.7
<b>Polyunsaturated FA, g/10 g ILE</b>					
Linoleic (18:2)	5.0	1.9	1.8	0.40	1.1
α-Linolenic (18:3)	0.90	0.24	0.20	<0.20	0.20
EPA (20:5)	0	0.24	0	2.0	1.0
Arachidonic (20:4)	0	0.05	0.03	0.25	0.14
DHA (22:5)	0	0.22	0	2.3	1.15
Phytosterols, mg/L	348 ± 33	47.6	237 ± 8	0	119
α-Tocopherol, mg/L	38	200	32	150–296	75–148

Intralipid, Omegaven, and SMOFlipid (Fresenius Kabi, Bad Homburg, Germany) and ClinOleic (Baxter, Maurepas, France). Data in the table are the mean value when an interval is given from the manufacturer. DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; ILE, intravenous lipid emulsions; MCT, medium-chain triglycerides.

# ENERGIA

- Lipideos
- Glicose
- AIG : iniciar 5 a 6 mg/kg/minuto
- PIG : iniciar 6 a 8 mg/Kg/minuto
- Cuidado com veia periferica nas altas concentrações de glicose

# CÁLCIO/FÓSFORO

TABLE I

Recommended intravenous intakes of calcium, phosphorus, and magnesium

Nutrient	Preterm infants*	Term infants	Children > 1 yr
<i>mg/L</i>			
Ca	500–600	500–600	200–400
P	400–450	400–450	150–300
Mg	50–70	50–70	20–40

\* To prevent Ca-P precipitation, intakes are described per liter, to prevent administration of high concentrations of Ca and P, which may result if intakes are expressed per kilogram body weight and there is fluid restriction. These recommendations also assume an average fluid intake of  $\sim 120\text{--}150 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$  with 25 g amino acid/L of a pediatric amino acid solution. These dosage levels for preterm infants should only be given in central venous infusions.

† Requirements are less with advancing age; few data available.

# VITAMINAS

**TABLE 2**  
Suggested intakes of parenteral vitamins in infants and children

Vitamin	Term infants and children Dose per day*	Preterm infants Dose/kg body wt (maximum not to exceed term infant dose)	
		Current suggestions†	Best estimate for new formulation‡
<b>Lipid soluble</b>			
A ( $\mu\text{g}$ )§	700	280	500
E ( $\text{mg}$ )§	7	2.8	2.8
K ( $\mu\text{g}$ )	200	80	80
D ( $\mu\text{g}$ )§ (IU)	10 400	4 160	4 160
<b>Water soluble</b>			
Ascorbic acid ( $\text{mg}$ )	80	32.0	25
Thiamin ( $\text{mg}$ )	1.2	0.48	0.35
Riboflavin ( $\text{mg}$ )	1.4	0.56	0.15
Pyridoxine ( $\text{mg}$ )	1.0	0.4	0.18
Niacin ( $\text{mg}$ )	17	6.8	6.8
Pantothenate ( $\text{mg}$ )	5	2.0	2.0
Biotin ( $\mu\text{g}$ )	20	8.0	6.0
Folate ( $\mu\text{g}$ )	140	56	56.0
Vitamin B-12 ( $\mu\text{g}$ )	1.0	0.4	0.3

\* These guidelines for term infants and children are identical to those of the AMA (NAG). MVI-Pediatric® (Armour) meets these guidelines. Recent data indicate that  $40 \text{ IU} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$  of vitamin D (maximum of 400 IU/d) is adequate for term and preterm infants (Koo et al, JPEN 1987;11:172-7) (23). The higher dose of  $160 \text{ IU} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$  has not been associated with complications and maintains blood levels within the reference range for term infants fed orally. This does not

# OLIGOELEMENTOS


**Table 2.** Enteral and parenteral recommendations (per kg/day) for ELBW and VLBW infants

Nutrient	Enteral recommendation	Parenteral recommendation	Content in 2 ml Peditrace®
Iron, mg	2–3	0–0.25	–
Zinc, mg	1.4–2.5	0.4*	0.5
Copper, µg	100–230	40*	40
Selenium, µg	5–10	5–7*	4
Manganese, µg	1–15	1*	2
Iodine, µg	10–55	10*	2
Chromium, µg	0.03–2.25	0.05–0.3*	–
Molybdenum, µg	0.35	0.25*	–

\* Approximate values. Iodine recommendation assumes no use of iodine containing antiseptics.

# CUIDADOS GERAIS

- Soluções comercialmente prontas – diminui erros
- Preparo em capela de fluxo laminar
- Cálcio e fosforo nas soluções
- Cálculos computadorizados diminuem erros
- Filtros de linha – protege pacientes contra precipitados – custo alto
- Proteção contra luz-proteção contra peroxidação
- Evitar uso de outras medicações na linha de parenteral
- Soluções 3:1



[www.newsweek.com](http://www.newsweek.com)

\$5.50 US \$4.50 Canada  
0 70628 01134 4  
3 9780706280113